Composition:
1 ml of suspension contains: active substance: dexamethasone 1.0 mg; excipients: benzalkonium chloride 0.1 mg; disodium hydrogen phosphate anhydrous 2.0 mg; polysorbate 80 0.5 mg; disodium edetate 0.1 mg; sodium chloride 7.0 mg; hypromellose 5.0 mg; citric acid monohydrate and / or sodium hydroxide to adjust pH; purified water to 1.0 ml.
Pharmacodynamics:
Dexamethasone is a synthetic fluorinated glucocorticosteroid that does not have mineralocorticoid activity. It has a pronounced anti-inflammatory, anti-allergic and desensitizing effect.
Dexamethasone actively suppresses inflammatory processes, inhibiting the release of inflammatory mediators by eosinophils, mast cell migration and reducing permeability, capillaries, vasodilation.
Pharmacokinetics:
When applied topically, it penetrates well into the corneal epithelium and conjunctiva: therapeutic concentrations are achieved in the aqueous humor of the eye; with inflammation or damage to the mucous membrane, the penetration rate increases.
Side effects:
With prolonged use of steroid drugs, the following can be observed: - increased intraocular pressure with possible subsequent development of steroid glaucoma with damage to the optic nerve and visual fields (therefore, when using drugs containing glucocorticosteroids, intraocular pressure should be regularly measured for more than 10 days); - the formation of posterior subcapsular cataract; - slowing down the healing process (for diseases that cause thinning of the cornea, its perforation is possible). Allergic reactions are possible. Secondary bacterial infection can occur as a result of suppression of the protective reaction of the patient's body.
In acute purulent diseases of the eye, glucocorticosteroids can mask or enhance the existing infectious process. Fungal lesions of the cornea tend to occur especially frequently with prolonged use of steroids.
The appearance on the cornea of non-healing ulcers after prolonged treatment with steroid drugs may indicate the development of fungal invasion. Features of the sale of prescription Special storage conditions Use within 4 weeks after opening the bottle.
Special conditions:
Eye drops contain a benzalkonium chloride preservative that can be absorbed by contact lenses. Before using the drug, contact lenses should be removed and put back no earlier than 20 minutes after using the drug. With a duration of therapy of more than 2 weeks, the condition of the cornea should be monitored.
Shake the bottle before use (eye drops). The bottle must be closed after each use. Do not touch the tip of the pipette to any surface.
Influence of the drug on the ability to drive vehicles and mechanisms: If the patient's vision is temporarily reduced after using the drug, it is not recommended to drive a car and engage in activities that require increased attention until it is restored.
Indications:
- Inflammatory diseases of the anterior segment of the eye: acute and chronic uveitis, iridocyclitis, iritis and cyclitis;
- blepharitis, keratoconjunctivitis, conjunctivitis - allergic, seasonal, catarrhal;
- prevention and treatment of inflammatory phenomena in the postoperative period;
- thermal and chemical burn (after complete epithelization of corneal defects).
Contraindications:
- Hypersensitivity to any of the components of this drug; - keratitis caused by Herpes simplex (treelike keratitis), chicken pox and other viral diseases of the cornea and conjunctiva;
- mycobacterial infections of the eyes;
- fungal diseases of the eyes;
- acute purulent eye diseases;
- damage to the integrity of the corneal epithelium;
- period of breastfeeding;
- age up to 18 years (safety and efficacy of the drug in children have not been investigated).
Pregnancy and lactation: There is no sufficient experience on the use of the drug during pregnancy. It is possible to use it for the treatment of pregnant women as prescribed by the attending physician if the expected therapeutic effect exceeds the risk of developing possible side effects.
Drug Interactions:
Interactions with other drugs are not currently known. In case of use with other local ophthalmic preparations, the interval between their use should be at least 10 minutes.
Dosage:
Locally. One or two drops in the conjunctival sac of the eye every 3-6 hours. Shake the bottle before use. You can combine the use of drugs "MAXIDE", eye ointment and "MAXIDE", eye drops: ointment - in the evening before bedtime, eye drops - during the day.
The duration of therapy is 2-3 weeks or as recommended by a doctor. The frequency of instillations and the duration of administration depend on the severity of the disease and the response to treatment. In severe inflammatory processes, it is necessary to install 1-2 drops of the drug every 30-60 minutes until a satisfactory response is achieved. In the absence of an answer, subconjunctival or systemic administration of glucocorticoids is necessary. Upon reaching a satisfactory response, the drug is administered 1 drop every 4 hours.
Overdose:
Symptoms: local manifestations are possible. Treatment: symptomatic.
